Navigating Increased Scrutiny for Health Care Deals in 2024
Health care deals continue to face scrutiny by the Department of Justice (DOJ), the Federal Trade Commission (FTC)—and now, the Department of Health and Human Services (HHS) and certain state agencies.
Join us for our webcast, Navigating Increased Scrutiny for Health Care Deals in 2024. Together with Moss Adams and America’s Physician Groups, we’ll address the new pressures facing health care systems, private equity investors, providers, and other stakeholders looking to complete a transaction in the health care ecosystem. We’ll discuss:
- Federal and state regulatory landscapes to review transactions and considerations for current and future deal activity.
- Unintended consequences this increased transactional scrutiny and added regulatory burden might have on market dynamics, deal confidentiality, and financially stressed organizations looking for survival options.
- Tension between reimbursement models and transaction pullbacks.
Moderated by
- Eric Klein, Partner & Leader, National Health Care Team, Sheppard Mullin
Panelists
- Bill Barcellona, J.D., MHA, EVP for Government Affairs, America's Physician Groups
- John Caroll, Partner, Antitrust and Competition Practice Group, Sheppard Mullin
- Jordan Grushkin, National Health Care Team and Leader of Firmwide OHCA Initiatives, Sheppard Mullin
- Chris Pritchard, CPA, MHA, Partner, Health Care Industry Group Leader, Moss Adams LLP
- Karl Rebay, MBA, Partner, Health Care Consulting, Strategy & Integration Leader, Moss Adams LLP